Partnering – November 2019
Interested to hear more about Cellestia's latest news? Join our COO, Dr. Maximilien Murone, at BIO-Europe (November 11–13, 2019), in Hamburg.
Science – October 2019
The NOTCH Meeting XI
Meet our COO, Dr. Maximilien Murone, at The NOTCH Meeting XI (October 6-10, 2019) in Athens. Key experts in the field of NOTCH research will be covering the breadth of science related to this topic.
2nd European Oncology and Immuno-Oncology Drug Discovery Symposium
Join us at the at Champions Oncology drug discovery symposium (October 22, 2019) in Basel. Our CSO, Dr Raj Lehal, will be giving a presentation that day (Discovery and development of a first-in-class protein-protein interaction inhibitor targeting the NOTCH pathway).
StartLab at Biopole Lausanne
Cellestia Biotech joined at StartLab at Biopole Lausanne in September 2019. Our R&D Lab is now fully operational.
Partnering – September 2019
Join us and meet our CFO Gaudenz von Capeller at Biopharm America, part of the Biotech week (September 11–12, 2019) in Boston.
19th Annual Biotech in Europe Forum (SACHS)
Join Cellestia’s team at the 19th Annual Biotech in Europe Forum (September 25–26, 2019) in Basel. Our CFO (Gaudenz von Capeller), COO (Maximilien Murone) and Head of Communication (Mathilde Claire Vincent) will be pleased to meet you.
Science – September 2019
Convergence in Oncology Summit
Our COO Maximilien Murone will be attending the Convergence in Oncology Summit at Biopôle (September 12–13, 2019) in Lausanne. The Convergence in Oncology Summit is an international annual assembly of industry leaders, entrepreneurs, and investors active in the field of Oncology to debate and explore synergies that can accelerate the development of the most promising solutions in the field.
European Society for Medical Oncology (ESMO) Congress
Meet Dr. Pavel Pisa, our Medical Director at ESMO Congress (September 27–October 1, 2019) in Barcelona.
ESMO 2019 will be the global stage for excellence in translational research, presentation of practice-changing data and multidisciplinary discussions.
Cancer Care 2019
Our CSO Rajwinder Lehal will give a presentation about Targeting undruggable oncogenic transcription factors, at Cancer Care (September 20, 2019, at 10 am) in Bern.
Join and meet him !
Board of Directors
9th International Conference – NOTCH Targeting in Cancer
Meet our CSO Rajwinder Lehal and attend the following sessions, at Grecian Park Hotel, Konnos Bay, Cyprus (June 26–28, 2019).
On 28th June, he will be chairing the Notch Therapeutics workshop together with Lucio Miele. He will also be giving a talk in Session 7 (Novel Therapeutics) at 4.30pm on Direct targeting of NOTCH Transcription Complex by a novel small molecule CB-103 circumvents dose limiting toxicities associated with pan-NOTCH inhibitors.
Partnering Meeting Bio€quity Europe
Meet the Cellestia team at the Bio€quity Europe meeting (May 20-21, 2019) in Barcelona.
American Association for Cancer Research Meeting
Cellestia selected for an oral presentation on CB-103 by Dr. Raj Lehal, Chief Scientific Officer, at the Preclinical Drug Development session of the American Association for Cancer Research Meeting (Atlanta, March 29–April 3).
IND accepted by the FDA
On Feb. 4th, Cellestia received the green light from the FDA for its Investigational New Drug Application (IND). The FDA completed its review, and concluded that Cellestia can proceed with its clinical investigation of CB-103 in tumors driven by an oncogenic NOTCH signaling pathway.
Cellestia Biotech AG secures CHF 20 million in Series A funding
Cellestia announced today the close of a CHF 20 million Series A financing round. The financing will accelerate Cellestia’s ongoing clinical program, and advance its innovative R&D pipeline.
To read Cellestia’s press release click here.